Evidence map›Paper›PMID 27683117›Full record

ArticleOncotarget2016

Fragile X mental retardation protein promotes astrocytoma proliferation via the MEK/ERK signaling pathway.

Zhou Xing, Minling Zeng, Huixian Hu, Hui Zhang, Zhuofang Hao, Yuesheng Long, Shengqiang Chen, Hang Su, Zhongmin Yuan, Meng Xu and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Zhou XingDepartment of Oncology, The First Affiliated Hospital, Jinan University, Guangzhou 510632, People's Republic of China.
Minling ZengDepartment of Neurosurgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, People's Republic of China.
Huixian HuTranslational Medicine Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, People's Republic of China.
Hui ZhangTranslational Medicine Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, People's Republic of China.
Zhuofang HaoDepartment of Pathology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, People's Republic of China.
Yuesheng LongInstitute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and Ministry of Education of China, Guangzhou Medical University, Guangzhou 510260, People's Republic of China.
Shengqiang ChenInstitute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and Ministry of Education of China, Guangzhou Medical University, Guangzhou 510260, People's Republic of China.
Hang SuTranslational Medicine Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, People's Republic of China.
Zhongmin YuanDepartment of Neurosurgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, People's Republic of China.
Meng XuDepartment of Oncology, The First Affiliated Hospital, Jinan University, Guangzhou 510632, People's Republic of China.
Jingqi ChenTranslational Medicine Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, People's Republic of China.
Guangzhou Medical University · CNFirst Affiliated Hospital of Jinan University · CNSecond Affiliated Hospital of Guangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo examine the association between fragile X mental retardation protein (FMRP) expression and astrocytoma characteristics.

methodsPathologic grade and expressions of glial fibrillary acidic protein (GFAP), Ki67 (proliferation marker), and FMRP were determined in astrocytoma specimens from 74 patients. Kaplan-Meier survival analysis was undertaken. Pathologic grade and protein levels of FMRP were determined in 24 additional patients with astrocytoma and 6 controls (cerebral trauma). In cultured U251 and U87 cell lines, the effects of FMRP knock-down on cell proliferation, AKT/mTOR/GSK-3β and MEK/ERK signaling were studied. The effects of FMRP knock-down on the volumes and weights of U251 cell-derived orthotopic tumors in mice were investigated.

resultsIn patients, FMRP expression was increased in grade IV (5.1-fold, P<0.01) and grade III (3.2-fold, P<0.05) astrocytoma, compared with controls. FMRP and Ki67 expressions were positively correlated (R2=0.877, P<0.001). Up-regulation of FMRP was associated with poorer survival among patients with FMRP integrated optical density >30 (P<0.01). In astrocytoma cell lines, FMRP knock-down slowed proliferation (P<0.05), inhibited total MEK levels P<0.05, and reduced phosphorylation of MEK (Ser217/221) and ERK (Thr202/Tyr204) (P<0.05). In mice with orthotopic tumors, FMRP knock-down decreased FMRP and Ki67 expressions, and reduced tumor volume and weight (36.3% or 61.5% on day 15, both P<0.01). Also, phosphorylation of MEK (Ser217/221) and ERK (Thr202/Tyr204), and total MEK in xenografts were decreased in sh-FMRP xenografts compared with non-transfected ones (all P<0.05).

conclusionEnhanced FMRP expression in astrocytoma may promote proliferation through activation of MEK/ERK signaling.

Indexed as

MAP Kinase Signaling SystemAdolescentAdultAgedAnimalsAstrocytomaBiomarkersCell Line, TumorCell ProliferationCell SurvivalChildChild, PreschoolDisease Models, AnimalFemaleFragile X Messenger Ribonucleoprotein 1Gene ExpressionBiomarkersFragile X Messenger Ribonucleoprotein 1Ki-67 Antigenastrocytomafragile X mental retardation proteinMEK/ERK signaling pathwayproliferationRNA interference

Identifiers

PMID27683117
PMCPMC5342749
OpenAlexW2521853540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.